31 January 2023
The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").
MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)
Trading Update
MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company transforming the environmental impact of industry, is pleased to announce its preliminary unaudited FY2022 results.
The Company exceeded previous guidance by achieving 2022 revenue of ca.$10.0 million, EBITDA of ca. negative $2.5 million and a net loss of ca.$4.0 million due to an increase in activity in the final month of the year which included an emergency response deployment in Saudi Arabia, higher than expected year end media sales and an increased scope for a REGEN project that was completed in December.
As at 31 December 2022, the Company had cash and cash equivalents of $1.65 million, and the Company continues to manage its working capital in support of future growth.
The financial information presented has been extracted from the unaudited results and could be subject to possible change following the completion of the Company's year-end audit process. MYCELX's final fully audited results are expected to be released in May 2023.
MYCELX has made an encouraging start to 2023, having secured a purchase order for a six-month paid trial for a PFAS remediation system for treatment of landfill leachate, a potentially large market segment for the Company's PFAS remediation offering. Subject to current market conditions continuing, the Company expects to meet current guidance for 2023.
Connie Mixon, CEO, commented:
"The financial results for 2022 show a slightly better than expected sales figure, as a result of an encouraging increase in activity at the end of the period. As reflected in our recent PFAS contract award, 2023 has started well and our growth this year remains focused on the Middle East, PFAS and REGEN. These are the core areas where we believe our technical expertise and track record of successful delivery will provide MYCELX with the best platform for future profitability."
For further information, please contact:
| MYCELX Technologies Corporation Connie Mixon, CEO Kim Slayton, CFO
|
Tel: +1 888 306 6843 |
| Canaccord Genuity Limited (Nomad and Sole Broker) Henry Fitzgerald-O'Connor Gordon Hamilton
|
Tel: +44 20 7523 8000 |
| Celicourt Communications (Financial PR) Mark Antelme Jimmy Lea |
Tel: +44 20 8434 2754 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.